Pages that link to "Q40843115"
Jump to navigation
Jump to search
The following pages link to Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial (Q40843115):
Displaying 50 items.
- Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (Q24242258) (← links)
- Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates (Q24802074) (← links)
- Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women (Q28307740) (← links)
- Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates (Q33569806) (← links)
- National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges (Q33572610) (← links)
- Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis (Q33607167) (← links)
- Successes achieved and challenges ahead in translating biomarkers into clinical applications (Q33954585) (← links)
- The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women (Q34029509) (← links)
- Biochemical markers of bone formation. (Q34032509) (← links)
- 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. (Q34300668) (← links)
- Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. (Q34373101) (← links)
- A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone (Q34429461) (← links)
- Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders (Q34435628) (← links)
- Treatment of postmenopausal osteoporosis: an evidence-based approach (Q34435633) (← links)
- Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis (Q35092602) (← links)
- Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition (Q35229974) (← links)
- Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury. (Q35418599) (← links)
- Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer (Q35569309) (← links)
- Osteoporosis management in the new millennium. (Q35692896) (← links)
- Evaluation and measurement of bone mass (Q35762723) (← links)
- Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis (Q35788591) (← links)
- A label-free electronic biosensor for detection of bone turnover markers (Q35796161) (← links)
- Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis (Q35828431) (← links)
- Alendronate sodium in the management of osteoporosis (Q35919111) (← links)
- Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses (Q36044183) (← links)
- Parathyroid hormone as an anabolic skeletal therapy (Q36316966) (← links)
- Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients (Q36463967) (← links)
- An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice (Q36567407) (← links)
- Prevention and treatment of osteoporosis in inflammatory bowel disease (Q36569260) (← links)
- Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial (Q36616992) (← links)
- Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls (Q36656424) (← links)
- Clinical challenges in the management of osteoporosis (Q36897449) (← links)
- Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis (Q37040841) (← links)
- Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis (Q37290052) (← links)
- Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development (Q37462448) (← links)
- Bone physiology, disease and treatment: towards disease system analysis in osteoporosis (Q37672603) (← links)
- Monitoring pharmacological therapy for osteoporosis (Q37689559) (← links)
- Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis (Q37738180) (← links)
- Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review (Q37867219) (← links)
- Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). (Q38059153) (← links)
- Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics. (Q38743204) (← links)
- An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide (Q39393975) (← links)
- Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis (Q40120012) (← links)
- The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study (Q40881729) (← links)
- Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation (Q43682728) (← links)
- Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens (Q44480315) (← links)
- Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using ass (Q44543470) (← links)
- Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. (Q44550203) (← links)
- User-only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures (Q44985602) (← links)
- Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus (Q45138817) (← links)